JCARH125

BIOLOGICAL2 trials

Sponsors

Juno Therapeutics, a Subsidiary of Celgene

Conditions

Chronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaMantle Cell LymphomaMultiple MyelomaNon Hodgkin Lymphoma

Phase 1

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

CompletedNCT03430011

Juno Therapeutics, a Subsidiary of CelgeneMultiple Myeloma

Start: 2018-02-01End: 2023-03-30Updated: 2024-05-24

Unknown Phase

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

TerminatedNCT03436771

Juno Therapeutics, a Subsidiary of CelgeneChronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +3

Start: 2018-02-19End: 2018-07-20Updated: 2020-05-04

Related Papers

Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

2025-06-031 citations

Early sBCMA Kinetics as a Potential Indicator of Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Patients Receiving CAR T-Cell Therapy

2025-02-18

Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research2025-01-214 citations

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

Journal of Clinical Oncology2021-05-2012 citations

Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Blood2020-11-0415 citations

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Blood2020-11-047 citations

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Journal of Clinical Oncology2020-05-20121 citations

Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma

Blood2019-11-1323 citations

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Blood2018-11-29124 citations